Highlights of This Issue  2919

SPECIAL FEATURES

CCR New Strategies

2921  New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

Molecular Pathways

2927  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

2932  Control of Tumorigenesis and Chemoresistance by the DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas

HUMAN CANCER BIOLOGY

2939  The Proapoptotic Molecule BLID Interacts with Bcl-X\textsubscript{L} and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

2948  The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma
Lili Li, Qian Tao, Hongchuan Jin, Andrew van Hasselt, Fan Fong Poon, Xian Wang, Mu-Sheng Zeng, Wei-Hua Jia, Yi-Xin Zeng, Anthony T.C. Chan, and Ya Cao

CANCER THERAPY: PRECLINICAL

2959  The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer Subtypes
Aurélié Docquier, Pierre-Olivier Harmand, Samuel Fritsch, Maïa Channion, Jean-Marie Darbon, and Vincent Cavailles

2971  Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma

2979  Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzetti, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

2989  Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

2999  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

The Journal of Clinical and Translational Research  iii www.aacrjournals.org
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3011</td>
<td>Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors</td>
<td>Alain C. Mita, Chris H. Takimoto, Monica Mita, Anthony Tolcher, Kamalesh Sankhala, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu-Nien Sun, Z. Don Zhong, Michael B. Bass, NgocDiep Le, and Patricia LoRusso</td>
</tr>
<tr>
<td>3028</td>
<td>Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer</td>
<td>Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., and Maha H.A. Hussain</td>
</tr>
<tr>
<td>3035</td>
<td>Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors</td>
<td>Bach Ardalan, Pochi R. Subbarayan, Yipsel Ramos, Michael Gonzalez, Anthony Fernandez, Dmitry Mezentsev, Isildinha Reis, Robert Duncan, Lisa Podolsky, Kelvin Lee, Mayra Lima, and Parvin Ganjei-Azar</td>
</tr>
<tr>
<td>3044</td>
<td>Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer</td>
<td>Tahlita C.M. Zuiverloon, Madelon N.M. van der Aa, Theo H. van der Kwast, Ewout W. Steyerberg, Hester F. Lingma, Chris H. Bangma, and Ellen C. Zwarthoff</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.